The Influence of Antiphospholipid Antibodies on the Pregnancy Outcome of Patients With Recurrent Spontaneous Abortion
Authors:
- 1 October 2001
- journal article
- clinical trial
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 7 (4) , 281-285
Abstract
Several therapeutic regimens have been proposed for women with recurrent spontaneous abortion (RSA) and antiphospholipid antibodies (APA). Conflicting results have been reported about women with history of RSA, positive APA, and failure of standard therapy. To evaluate the use of intravenous immunoglobulin in RSA patients with APA and history of treatment failure, we initiated a study with standard therapy (aspirin and low-molecular- weight heparin) and intravenous immunoglobulin. We used an enzyme-linked immunosorbent assay (ELISA)test to screen IgG and IgM anticardiolipin antibodies, and a diluted Russel viper venom time assay for the lupus anticoagulant activity. Altogether. 66 pregnant women with positive APAs at the first visit could be included. Patients with hereditable thrainbaghilic factors were excluded. After confirmation of the pregnancy, women received a basis immunization of 0.3 g/kg immunoglobulin in a 4-week cycle until the 28th to 32nd week of gestation. All patients received 100 mg/d aspirin and 3,000 anti-Xa U/d certoparin. Among the 66 pregnant women, 17 were persistently autoantibody positive (25.8%), of whom 11 (16.7%) were ACA positive alone, 2 (3%) were lupus anticoagulant positive, and 4 (6.4%) had both antibody types. A total of 49 patients had positive APAs at the initial test, but were negative for ACA and lupus anticoagulant at the second test administered approximately 5 weeks after the start of therapy. We described this group in our following observation as "antibody negative." Sixteen of the 17 autoantibody-positive patients (94.1 %) were delivered of live infants compared with 40 patients (81.6%) in the antibody-negative group (odds ratio [OR]: 1.2; 95% CI: 0.98 to 1.4). The overall miscarriage rate was 12.1% and the fetal loss rate was 15.2%. Four patients (25%) in the antibody-positive group developed symptoms of preeclampsia and fetal growth retardation compared with four patients (9.8%) in the antibody-negative group. In conclusion. we see a reduction of the fetal loss rate in patients with RSA and positive APA (5.8%) compared with APAnegative (18.4%) women with the same therapy (OR: 0.3; 95% CI: 0.04 to 2.3).Keywords
This publication has 33 references indexed in Scilit:
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a reviewScandinavian Journal of Rheumatology, 1998
- Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)BMJ, 1997
- Antiphospholipid antibody–associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin aloneAmerican Journal of Obstetrics and Gynecology, 1996
- Immunotherapy for Recurrent Pregnancy Loss: Analysis of Results From Clinical TrialsAmerican Journal of Reproductive Immunology, 1996
- Intravenous immunoglobulin infusion therapy in women with recurrent spontaneous abortions of immune etiologiesJournal of Reproductive Immunology, 1995
- Intravenous immunoglobulin in the prevention of recurrent miscarriageBJOG: An International Journal of Obstetrics & Gynaecology, 1994
- Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patientsAmerican Journal of Obstetrics and Gynecology, 1993
- The use of intravenous gammaglobulin, herparin and aspirin in the maintenance of pregnancy of freeze thawed embryo in a patient with lupus-type anticoagulantEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1993
- Intravenous immunoglobulin treatment for recurrent abortions caused by antiphospholipid antibodiesFertility and Sterility, 1991